Todd Kelsey
Analyst · Mitch Steves. Mitch, your line is open
Thank you, Dean. Good morning. Please advance to slide 7, for insight into the performance of our market sectors during Q1 of FY '16, as well as our expectations for the sectors in Q2 of FY '16. Our networking/communication sector was down 12% sequentially in Q1 which was better than our expectations of down in the high teens. Four of our top five customers in this sector performed better than our expectations as we entered the quarter, while performance in the remainder of this sector was mixed. Looking to Q2, we expect networking/communications revenue to be down in the mid single-digit percentage point range, as we continue to wind on the program we discussed previously. Excluding this program, there is modest underlying growth in the sector, primarily driven by an improving forecast from one of our top customers. Overall demand within the sector remains volatile and we expect revenue from 7 of our top 10 customers to be down from Q1. Our healthcare/life sciences sector was up 4% sequentially in Q1, slightly above our expectations of a low single-digit increase. Demand was relatively stable within the quarter. Looking ahead to fiscal Q2, we currently anticipate revenue in our healthcare/life sciences sector to be flat to Q1, as end market softness offsets the benefit of new program ramps. We expect sequential growth in the back half of the fiscal year as new programs mature. Our industrial/commercial sector was down 14% sequentially in fiscal Q1, slightly worse than our expectations of down low teens as a result of broad-based end market weakness. 8 of our 10 ten customers were down sequentially in the quarter. We currently anticipate that our industrial/commercial sector will be up in the low single-digit percentage point range in our fiscal Q2, as we see modest near-term strengthening in the semiconductor capital equipment space and benefit from new program ramps. As we look to the back half of FY '16, we anticipate strong sequential growth due to significant new program ramps with multiple customers. Our defense/security/aerospace sector was down 10% sequentially in Q1, a result that was below our expectations of a low single-digit decline. Several aerospace customers reduced demand from our expectations at the beginning of the quarter. We currently expect Q2 to be up in the mid single-digits, as new program ramps offset near-term inventory corrections. We remain positioned for solid growth within the sector in FY '16. While our forecast volatility over the course of FY '16 varies considerably by market sector, our overall revenue forecast had remained remarkably consistent since the last earnings release. Our quarterly revenue expectations throughout FY '16 remain largely unchanged from our outlook in October. Next to new business wins on slide 8. During the quarter, we won 34 new programs in our manufacturing solutions group that we anticipate will generate approximately $179 million in annualized revenue when fully ramped in production. From an absolute standpoint, the wins for our Americas region were quite encouraging at $108 million. In addition, when reviewing the trailing four quarter wins as a percentage of the trailing four quarter revenue, our EMEA region has particularly strong wins momentum. As a result, we expect meaningful growth in the region in FY '16 and beyond. Please advance to slide 9 for further insight into the wins performance of our market sectors. It is important to note that there is significant volatility in the quarterly results and longer-term trends provide the most value in measuring sector performance. In fiscal Q1, our manufacturing solutions wins were robust in industrial/commercial and healthcare/life sciences market sectors. When reviewing the trailing four quarter wins as a percentage of the trailing four quarter revenue, the healthcare/life sciences, defense/security/aerospace and industrial/commercial sectors all display wins momentum well below above our 25% goal, supporting our long-term growth and continued transformation to a healthier, more defensible portfolio. Now advancing to wins momentum on slide 10. Our trailing four quarter manufacturing wins, as shown by the dark blue bars is at $702 million. This performance results in a trailing four quarter win ratio of 27% relative to trailing four quarter revenue, above our target of 25% and consistent with the prior two quarters. Our engineering solutions wins totaled approximately $22 million in fiscal Q2. Our engineering wins remain strong in our healthcare/life sciences sector, where our complete value stream of product realization solutions differentiates in the marketplace. Please advance to slide 11. Our funnel of qualified manufacturing opportunities is at a two-year high of $2.3 billion. On a sector basis, our healthcare/life sciences and industrial/commercial funnels are exceptionally, consistent with our goal of expanding share within these sectors in order to deliver a healthier portfolio. Next I would like to turn to operating performance on slide 12. As expected, our fiscal Q1 revenue was down considerably from Q4 of FY '15. Despite the revenue contraction, our operating margin finished above our guidance range at 3.7%, as a result of the solid initial progress associated with our cost reduction and productivity improvement initiatives. While we're guiding revenue essentially flat for fiscal Q2, our underlying book of business is up approximately 4% sequentially, when factoring out the two low margin programs disengagements we previously discussed. Please advance to slide 13 for additional insight into our future operating margin expectations. Consistent with our discussion last quarter, we have put in place plans to improve operating profit $6 million to $8 million per quarter by Q3 of FY '16. We're currently modestly ahead of schedule. We achieved a 20 basis point improvement to fiscal Q1 operating margin, as a result of our immediate focused actions on reducing discretionary spending, reducing operating expenses and achieving near-term productivity gains. As we look forward to fiscal Q2, we will continue to make progress with our cost reduction and productivity improvement initiatives. However, much of these gains will be offset by the typical 40 basis points seasonal headwinds, inclusive of compensation adjustments and United States payroll tax reset. Looking ahead to the remainder of FY '16, we will recognize the benefits from our previously announced Fremont facility closure and Livingston facility restructuring, as well as the full impact of the productivity improvements in each of our regions. Inclusive of the seasonal costs, we expect cost reduction and productivity improvement actions will have a cumulative impact to operating margin of about 100 basis points. We anticipate additional positive margin benefit in FY '16 from our Guadalajara ramp and sustained growth in the EMEA region. Our Guadalajara ramp continues to progress well, as the site is currently approaching $200 million run rate with sustained profitability. Customer satisfaction at the site is excellent and we continue to win new business. In addition, our funnel of new business opportunities at the site remains robust. We currently expect reasonable sequential revenue growth in the second half of the fiscal year. However, we will continue to evaluate our cost structure as the year unfolds. We remain committed to achieving our target operating margin range of 4.7% to 5% and are working diligently to achieve that goal within FY '16. I will now turn the call to Pat for a more detailed review of our financial performance. Pat?